An award-winning journalist and New York Times best-selling author, David Faber is a co-anchor of CNBC's "Squawk on the Street" (M-F: 9 a.m.-12 p.m. ET) and an anchor and co-producer of CNBC's acclaimed original documentaries and long-form programming.
During the day, Faber breaks news and provides in-depth analysis on a range of business topics during the "Faber Report." In his 20 years with CNBC, Faber has broken many big financial stories including the massive fraud at WorldCom, the bailout of the hedge fund Long Term Capital Management and Rupert Murdoch's unsolicited bid for Dow Jones.
Faber has reported nine documentaries for CNBC for which he has received Loeb, Emmy, Peabody and duPont awards.
His book, "The Faber Report," was published by Little, Brown in spring 2002; his second book, "And Then the Roof Caved In," was published in the summer of 2009 by John Wiley.
He holds a bachelor's degree in English from Tufts University.
Follow David Faber on Twitter @DavidFaber.
While the battle over the NYSE rages and we wait for a response from that exchange to the proposed $42.50 dual stock and cash bid from Nasdaq and Ice, it’s worth mentioning that among the most likely outcomes here is that the NYSE doesn’t get bought at all.
It seems likely that in the next 24 hours we will receive Cephalon’s response to the $73-a- share all cash offer it received last week from Valeant. From what I’m hearing, that response could likely include a rejection of Valeant spacer and a plan from Cephalon to seek out parties other than Valeant that would be interested in purchasing it.
The late day announcement Monday from Texas Instruments sayings it’s buying National Semiconductor spacer has tech investors laser focused on one thing: the huge premium that TI is paying.
The somewhat improbable, though long-awaited bid from Nasdaq and ICE came Friday with the desired effect. It sent shares of the NYSE up sharply (not to mention shares of the Nasdaq) and has changed the dynamic. Anyone expecting a swift resolution of this contest, however, is likely to be disappointed.
Berkshire Hathaway has agreed to purchase chemical company Lubrizol in a $9 billion cash deal worth $135 per LZ share, the two companies said Monday.